elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Pricing
Log in
Sign up
Home
/
Subjects
/
Radioligand
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Radioligand
RIS
0.006
(Research Intensity Score)
Papers
859
Top papers
Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)
2023 · 281 citations
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study
2024 · 195 citations
[177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer
2022 · 301 citations
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
2023 · 115 citations
Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy
2023 · 108 citations
177Lu-LNC1004 Radioligand Therapy in Patients with End-stage Metastatic Cancers: A Single-Center, Single-Arm, Phase II Study
2025 · 37 citations
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177 Lu-PSMA I&T and 177 Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry
2021 · 185 citations
Recent advances in theranostics and oncology PET: emerging radionuclides and targets
2025 · 26 citations
Long-Term Nephrotoxicity of 177 Lu-PSMA Radioligand Therapy
2023 · 67 citations
Newest papers
PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions
2026 · 5 citations
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
2026 · 4 citations
Prostate Cancer, Part 1: Contemporary Radioligands
2026 · 3 citations
Data from Clonal Hematopoiesis after <sup>177</sup>Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
2026 · 1 citations
Preclinical evaluation of novel 177Lu-labeled fibroblast activation protein inhibitor with albumin binder for radioligand therapy
2026 · 2 citations
A Spatiotemporal Image-Guided Model of Radiopharmaceutical Transport in Heterogeneous Vasculature Prostate Tumor: A Computational Analysis of Key Parameters in Lutetium-177 PSMA Therapy
2026
Current practice in reporting internal dosimetry for [177Lu]Lu-PSMA radioligand therapy: a systematic review
2026
Optimizing FAPI homodimers for theranostic applications: The impact of the linker design in DOTAGA.Glu2.(FAPI)2 and DOTAGA.PEG2.Glu.(FAPI)2
2026
PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) TARGETED THERAPIES IN THE TREATMENT OF PROSTATE CANCER: ADVANCES, EFFICACY, AND FUTURE DIRECTIONS
2026
Browse all papers →
Radioligand's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Radioligand's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link